Abstract

Previous reports have shown various neurological manifestations in about 36.4% of patients infected with SARS-Cov-2. However, peripheral neuropathy was only reported once before.A 40-year-old healthy woman presented with two weeks of cough, nasal congestion, sore throat, intermittent fevers, fatigue, and myalgia but no weakness. She tested positive for the SARS-Cov-2. Physical exam showed no neurologic deficit. Two weeks later, respiratory symptoms were improving but she developed sudden leg pain, numbness, and weakness. She described it as a “pain crisis”. Neurological exam showed bilateral symmetrical, non-ascending lower extremity weakness and normal, symmetric reflexes. She had normal magnetic resonance imaging of the brain and spine, spinal fluid analysis, serum studies including creatinine kinase and C-reactive protein. She had elevated lactate dehydrogenase, low serum copper (72.9 (ref: 80.0-155.0 ug/dL)) and low vitamin B6 (14.6 (ref: 20.0-125.0 nmol/L)). A diagnosis of SARS-Cov-2-associated peripheral neuropathy was considered. We pursued empiric treatment with intravenous steroids (1000 mg methylprednisolone for three days), followed by a total of 2 g/kg of intravenous immunoglobulins (IVIG) given over five days. Pain management was done with gabapentin and ketorolac. We replaced copper and vitamin B6. Six weeks later, she reported improvement and was closer to baseline, but she endorsed residual, exertional, mild bilateral lower extremity pain, numbness, and weakness.Previous reports of treatment of SARS-Cov-2-associated neuropathy included corticosteroids and IVIG. Our patient saw the most symptomatic improvement with gabapentin. In our case, the preserved reflexes, lack of ascending pattern, sudden onset of symptoms, and normal cerebrospinal fluid (CSF) argued against Guillain-Barre syndrome. Copper deficiency can result in myelopathy but not peripheral neuropathy, so is unlikely the sole explanation. Awareness and early treatment of peripheral neuropathy in SARS-Cov-2 can result in improved clinical outcomes for patients.

Highlights

  • The spectrum of neurologic complications following the novel coronavirus 2 (SARS-Cov-2) infection is ever expanding

  • COVID-19, caused by the infection with the SARS-Cov-2, has become a global pandemic affecting more than 210 countries and the number of confirmed and fatal cases is on the rise [1]

  • We reported a case of mixed sensorimotor neuropathy in association with SARS-Cov-2 infection with near complete resolution with immune-modulation, symptomatic therapy and intensive rehab

Read more

Summary

Introduction

The spectrum of neurologic complications following the novel coronavirus 2 (SARS-Cov-2) infection is ever expanding. A healthy 40-year-old woman presented with two weeks of cough, nasal congestion, sore throat, intermittent fevers, myalgia, generalized weakness, and fatigue Two weeks later her pulmonary symptoms improved but she developed sudden, severe bilateral leg pain, numbness, and weakness. We administered gabapentin at 100 mg nightly, duloxetine at 30 mg twice daily, tramadol at 50 mg, and as needed ketorolac resulting in some pain control. This was coupled with intensive rehabilitation and copper replacement. At week 4, her “pain crisis” resolved, but continued to have chronic pain rated at a 4-6/10 She had persistent myalgia, weakness, numbness, and tingling.

Discussion
Findings
Conclusions
Disclosures
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call